StockData
GSK plc logo

GSK plc (GLAXF) stock analysis

GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)

Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –

StockData Score

Prices as of Oct 30, 2026How the score works

Value0Growth2Performance4Health3Dividend0

Mixed9 of 30 checks passed

GSK passes 9 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
4/6
Financial health
3/6
Dividend
0/6

What stands out

  • Return on equity over 15%

    Return on equity was 38.0% over the last twelve months and averaged 48.9% over five years.

  • Return on capital over 10%

    Return on invested capital was 23.4%, above the 10% that usually covers the cost of capital.

  • Earnings growth accelerating

    Net income grew 122% over the last twelve months, against a 5-year average of -0.1% a year.

  • Interest well covered

    Operating income covers interest expense 11.3 times.

What to watch

  • High debt

    Debt is 108% of shareholders' equity, above the 40% we consider low.

  • Earnings shrank over 5 years

    Net income shrank 0.1% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew 3.7% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -27.6% a year over the last three fiscal years.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew 3.7% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -27.6% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 122% over the last twelve months, against a 5-year average of -0.1% a year.

  • Growing slower than the industry

    Revenue grew 4.1% over the last twelve months; the Drugs median is 6.8%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 72.4% over the last twelve months, against 71.2% a year earlier.

Past performance4/6

  • Return on equity over 15%

    Return on equity was 38.0% over the last twelve months and averaged 48.9% over five years.

  • Return on capital over 10%

    Return on invested capital was 23.4%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    GSK's return on equity of 38.0% is above the Drugs median of -59.0%.

  • Earnings shrank over 5 years

    Net income shrank 0.1% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was 17.5% over the last twelve months, against a 5-year average of 22.1%.

  • Net margin above the industry

    GSK's net margin of 17.5% is above the Drugs median of -59.9%.

Financial health3/6

  • High debt

    Debt is 108% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 186% five years ago to 108%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 43.7% of total debt.

  • Interest well covered

    Operating income covers interest expense 11.3 times.

  • Short-term assets don't cover short-term debts

    Current assets are 0.82 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    GSK has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for GSK. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$257.95M
Value traded per 1% price move
$137.87M

Downside

Low risk

Typical loss in a bad month
13.6%
Volatility (annualized)
26%
Sharpe ratio, 1 year
0.13
Beta to the S&P 500 (5Y)
0.26

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2015 to 2025

Gross margin

72.4%+5.0 pts over 5 years

Operating margin

24.3%−0.3 pts over 5 years

Net margin

17.5%−6.1 pts over 5 years